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DNA methylation is an epigenetic regulation mechanism of genomic function, and aberrant methylation pattern has been found
to be a common event in many diseases and human cancers. A large number of cancer studies have been focused on identiﬁcation
of methylation changes as biomarkers (i.e., breast cancer). However, still clinical use of them is very limited because of lack of
speciﬁcity and sensitivity for diagnostic test. This highlights the critical need for speciﬁc primer and probe design to avoid false-
positive detection of methylation proﬁling. The guideline and online web tools that are introduced in this paper might help to
perform a successful experiment and to develop speciﬁc diagnosis biomarkers by designing right primer pair and probe prior to
experimental step.
1.Introduction
DNA methylation of cytosine located 5  to a guanosine is
one of the most important modiﬁcations of genomic DNA
in eukaryotic cells. Methylation of cytosine at CpG dinu-
cleotides is described as an epigenetic regulation mechanism
of genomic function that plays an important role in diﬀerent
biological processes including embryogenesis [1], genomic
imprinting [2], X-chromosome inactivation, and cancer
[3, 4].
Aberrant methylation pattern has been found to be a
common event in many cancers [5–7]. Global hypomethy-
lation is considered to play a role in carcinogenesis; how-
ever, local hypermethylation changes gene expression [8].
This hypermethylation alteration resulted in transcriptional
inactivation followed by silencing of promoter at nearby
tumor suppressor genes, contributing to development of
cancer. The hypermethylation was thought to be an early
event in carcinogenesis [9–12]. A large number of studies in
cancers including breast cancer have focused on the use of
CpG island hypermethylation proﬁling as cancer biomarkers
in tissue and circulating cell-free DNA of patients, with
the aim of improving cancer treatment via accurate early
diagnosis, noninvasive diagnosis, prognosis, and prognosis
therapy selection [7, 13–18].
Recent technology development has provided the anal-
ysis of DNA methylation in a genome-wide scale [19, 20]
which may not be easily accessible for many institutions.
Thereby, in most of the research centers methylation assays
can be only determined on gene-by-gene-based methods
that use bisulﬁte conversion. The bisulﬁte reaction was ﬁrst
described in early 1970s [21, 22]. Since the ﬁrst description
of bisulﬁte reaction in the application of studying CpG
sites, many methods based on the same principle have been
developed and categorized according to primer designing
strategies. Based on primer designing strategies two dif-
ferent DNA methylation assays are described, methylation-
independent-speciﬁc PCR (MIP) primers and methylation-
speciﬁc PCR (MSP) primers [23].
Primer and probe design for methylation assays based
on bisulﬁte conversion is challenging because of the DNA
composition after bisulﬁte modiﬁcation. One of the most
critical steps for methylation study is designing primers and
probes for the modiﬁed DNA and it needs special constrains
on primers or probe and their location on the DNA. A large
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biomarkers; however, the clinical use of these biomarkers is
still very limited because of lack of speciﬁcity and sensitivity
for diagnostic test. This highlights the critical need for
speciﬁc primer and probe design to avoid false-positive
detection of methylation.
We review a brief guideline of CpG island prediction,
designing primers and probes for MIP and MSP assays that
are used for methylation studies based on bisulﬁte conver-
sion. Some important web-tools for methylation studies are
introduced as well.
2. CpG Island Prediction
Methylation at the cytosine bases of CpG dinucleotide-rich
region mostly within 0.5–4kb are known as CpG islands
[24, 25]. Although analysis of the methylation status of
some critical CpG sites as biomarkers are better than others,
it is essential to ﬁnd CpG islands at the promoter region
of candidate genes which are in close proximity to the
transcription start site.
In order to predict CpG islands as target region, the fol-
lowing rules should be applied.
(I) If CpG island prediction is used for primer design
and more than one island is found, any of the
predicted islands can be a target region for primer
selection.
(II) If a CpG island size is smaller than the minimum
product size, the primer pair should span the whole
island.
(III) If a CpG island size is greater than the maximum
product size, the primer pair should be within the
island.
(IV) If a CpG island size is between the minimum and
maximum product size, at least two thirds of the
island region should be ampliﬁed.
3. Methylation-Independent-Speciﬁc
PCR(MIP) Primers
MIP primers are used in diﬀerent PCR-based methyla-
tion analysis methods including bisulﬁte-sequencing PCR
(BSP) (in 1992, [26]), pyrosequencing [27, 28], combined
bisulﬁte restriction analysis (COBRA) [29], methylation-
sensitive single-nucleotide primer extension (MS-SnuPE)
[30–32], methylation-sensitive melting curve analysis (MS-
MCA) [33], methylation-sensitive high-resolution melting
(MS-HRM)[34],matrix-assistedlaserdesorption/ionization
time-of-ﬂight (MALDI-TOF) mass spectrometry with base-
speciﬁccleavageandprimerextension[35,36],heavymethyl
[37], and microarray DNA methylation proﬁling technique
based on bisulﬁte conversion, that is, methylation-speciﬁc
oligonucleotide microarray (MSO) [38].
Incomplete bisulﬁte modiﬁcation of DNA is sometimes a
concern [39] and results in high representation of methyla-
tion levels in studied samples. Successful application of MIP
methods depends on whether PCR primer could be designed
to amplify the complete modiﬁed fragment of interest.
Table 1: The main characteristics for primer/probe designing in
DNA methylation proﬁling techniques based on bisulﬁte conver-
sion.
Primer/Probe Main characteristics
MIP primer
(i) No CpG sites within the sequence.
(ii) Including an adequate number of “C”s
(no-CpG) in the sequence.
(iii) Spanning a maximal number of CpG sites in
the amplicon.
(iv) Long length primer (25–30mer).
(v) Amplicon size maximum 500bp.
MSP primer
(i) Containing as much CpG sites as possible
especially at 3 -end of the primer.
(ii) Considering the same CpG sites in the primer
sequence for methylated DNA and
unmethylated DAN primers.
(iii) Similar Tm values for both the methylated
DNA and unmethylated DAN primers.
(iv) Amplicon size maximum 500bp.
Probe
(i) Including CpG sites to maximize speciﬁcity.
(ii) Including several “C”s (no-CpG) in the
sequence.
(iii) Probes length 15–30mer.
(iv) Amplicon size 50–150bp (max 300bp).
Toreducebiasofbisulﬁte-modiﬁedDNAagainstunmodiﬁed
or incompletely modiﬁed DNA or even unsuccessful exper-
imental PCR optimization, primer pair should be picked
from a region that have adequate number of cytosines “C”s
(no-CpG) in the original sequence [40]. Primer pairs with
more “C”s will be preferred by receiving higher weighing
scores and increasing the annealing temperature (Table 1).
Besides general consideration for designing primer pair, the
following constraints are enforced for MIP primer design.
(I) Primers should not contain any CpG sites within
their sequence to avoid discrimination against meth-
ylated or unmethylated DNA (Figure 1).
(II) Primers should have an adequate number of “C”s
(no-CpG) in their sequence to amplify only bisulﬁte
modiﬁed DNA. Primers with more “C”s will be
preferred (at least 30%) [40]( Figure 1).
(III) A good primer pair should span a maximal number
of CpG sites in the selected amplicon to map as many
CpG sites as possible.
(IV) If CpG island prediction is not used for primer
selection, selected amplicons must span at least
5CpG sites as a default.
(V) Long length primer (25–30mer) is preferred to
ensure uniqueness of the primer [39].
(VI) Primer sets should not amplify more than 500bp
because DNA degradation occurs by bisulﬁte modi-
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Figure 1: Primer design for DNA methylation proﬁling techniques based on bisulﬁte conversion. (a) First DNA is treated with sodium
bisulﬁtetoconvert all unmethylated cytosines to uracil. Toanalyze DNA methylation status of theinterest genes, converted DNA is ampliﬁed
based on two diﬀerent primer designing strategies: methylation-independent speciﬁc PCR (MIP) and methylation-speciﬁc PCR (MSP). (b)
In MIP, DNA molecules are ampliﬁed using primer pairs containing cytosines (no-CpG) in their sequence. (c) In MSP, primer pairs are
designed to speciﬁcally amplify either methylated (M) or unmethylated (U) DNA by containing CpG site in their sequence that makes
possible to distinguish the methylated sequence from the unmethylated sequence.
4.Methylation-SpeciﬁcPCR (MSP)Primers
Methods based on MSP primers are considered to have the
highest analytical sensitivity and are designed to speciﬁcally
amplify either methylated or unmethylated DNA by using
primers that distinguish the methylated sequence from
the unmethylated sequence [23, 40]. The precision and
sensitivity of MSP depends on appropriate primer or probe
design not prone to false-positive results [23]. MSP primers-
based methods include methylation-speciﬁc PCR (MSP)
[40], methylight [41, 42], SYBER green-based quantitative
MSP [43, 44], sensitive melting analysis after real-time MSP
(SMART-MSP) [45], and methylation-speciﬁc ﬂuorescent
amplicon generation (MS-FLAG) [46]. The speciﬁcity of
methylation-based PCR methods is achieved by appropriate
primer pair or probes design (Table 1). The following
constraints are recommended to reduce false-priming events
for ampliﬁcation of methylated DNA.
(I) To discriminate between a methylated and unmethy-
lated DNA fragment, primers have to contain as
much CpG sites as possible (at least one CpG)
preferably at the very 3 -end. At least one of the last
three bases at 3 -end of the primer has to be a CpG
“C” (Figure 1).
(II) A part from CpG site(s) at the very 3 -end, addi-
tional CpG sites in a primer sequence is preferred
(Figure 1).
(III) Primers for methylated DNA and unmethylated
DNA should contain the same CpG sites in their
sequence. For example, a forward primer for
methylated pair has this sequence: ATAAGTATT
CGTTAATGGTTCGA, the forward primer in the
unmethylated pair must also contain the two CpG
sites, for example, ATAAGTATTTGTTAATGGTT
TGA. But they may diﬀer in length and start position
[3].
(IV) The two sets of primers for methylated and unmeth-
ylated DNA should have similar Tm values (max Tm
diﬀerence 5◦C).
(V) Elimination of secondary structure formation and
primer-dimer pairs by increasing primer length.
(VI) Primer sets should not amplify more than 500bp
because DNA degradation occurs by bisulﬁte modi-
ﬁcation.
False-priming eventcan beprevented bydesigning appropri-
ateprimersandincreasingannealingtemperature.Havingan
appropriate negative control in the experiment might help to
ﬁnd out false-priming events.
5. Guidelinesfor ProbeDesigning
In methylation studies, the discrimination between methy-
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design of primers that contain or does not contain CpG
sites, design of ﬂuorescent labeled probe (for instance
MSO and bead array), and design of the both primer
and probe, that is, methylight technology [41]. MIP and
MSP methods are associated with false positive results. By
using ﬂuorescent probes, for instance methylight method-
ology or applying heavy methyl probe-based method-
ology, the false positives can be limited. Using probe
as a detection method increases the speciﬁcity to dis-
criminate between methylated and unmethylated DNA
by designing probes that contain additional CpG sites
[40]. The selection of new primer pairs for methylation-
speciﬁc PCR and suitable hybridization probes for real-
time PCR-based assays require the identiﬁcation of the
CpG sites that are methylated (Table 1). Moreover, using
probe provides possibility to detect more than one target
with multiplex reaction by diﬀerent reporter dyes [38,
47].
In addition probe-based assays can provide quantitative
information; further advantages are the speed and high
throughput of the 96-well-based, real-time PCR system
and the omission of all postampliﬁcation steps, which
has less labour and the risk of contamination. Also, the
eﬃciency of individual reactions is accessible from the
slope of the ampliﬁcation plot in the logarithmic phase.
This allows for the direct quality control of every ampli-
ﬁcation reaction and the identiﬁcation of samples con-
taining impurities or poor template that interfered with
optimal ampliﬁcation and thereby with the quantiﬁcation
[48].
A general guideline for probe designing is described as
follows.
(I) The probe sequences should include 3 to 5 potential
methylation sites to maximize speciﬁcity and reduce
false-priming event.
(II) The probe binding sites should include several
cytosines in the original sequence to ensure speci-
ﬁcityforconvertedDNAandovercomefalsepositives
due to incomplete bisulﬁte conversion.
(III) Long repetitive stretches should be avoided.
(IV) Probe Tm value should be 10◦C higher than primers.
(V) G + C content should be 30%–80%.
(VI) No G should be at the 5  end.
(VII) Probes should have 15–30mer in length.
(VIII) No more than two G + C should be at the 3  end.
(IX) Amplicon size should be 50–150bp (max 300bp).
The PCR products should be as short as possible,
to maximize eﬃciency (especially important for the
analysis of fragmented DNA isolated from formalin-
ﬁxed, paraﬃn-embedded biopsies, and circulating
cell-free DNA).
6. Online WebTools for Methylation Study
6.1. DNA Methylation Analysis Databases
(i) Entrez Gene: (http://www.ncbi.nih.gov/entrez).
(ii) GDB: Human Genome Database (http://www.gdb
.org/).
(iii) DNA methylation database: public resource to
store and standardise DNA methylation data
(http://www.methdb.de/).
(iv) methBLAST: similarity search program designed to
explore in silico bisulﬁte modiﬁed DNA, either or
not methylated at its CpG dinucleotides (http://
medgen.ugent.be/methBLAST/).
(v) DNA Methylation Society: an international scientiﬁc
society open to all those interested in any aspects of
biological methylation (http://www.dnamethylation
.net/).
6.2. Promoter Prediction Tools
(i) FirstEF: ﬁrst-exon and promoter prediction
program for human DNA (http://rulai.cshl.org/
tools/FirstEF/).
(ii) Promoter 2.0 Prediction Server: Promoter 2.0 pre-
dicts transcription start sites of vertebrate PolII
promoters in DNA sequences (http://www.cbs.dtu
.dk/services/Promoter/).
(iii) WWW Promoter Scan: predicts Promoter regions
based on scoring homologies with putative eukary-
otic Pol II promoter sequences (http://thr.cit.nih
.gov/molbio/proscan/).
(iv) McPromoter MM: The Markov Chain Promoter
Prediction Server. McPromoter is a program aiming
at the exact localization of eukaryotic RNA poly-
merase II transcription start sites (http://genes.mit
.edu/McPromoter.html).
6.3. CpG Island Prediction Tools
(i) CpG Island Searcher (http://cpgislands.usc.edu/).
(ii) CpG Plot (http://www.ebi.ac.uk/emboss/cpgplot/).
(iii) MethPrimer (http://www.urogene.org/methprimer/).
(iv) CpGProD (CpG Island Promoter Detection): CpG-
ProD is a mammalian-speciﬁc software which pro-
poses to identify the promoter regions associated
with CpG islands (CGIs). CpGProD uses the struc-
tural characteristics of the CGIs associated with
promoters (start CGIs). In the ﬁrst step, CpGProD
searches for all the CGIs located over the sequences
and, in the second step, CpGProD identiﬁes start
CGIs and orientation of the potential promoters
(http://pbil.univ-lyon1.fr/software/).
(v) CpG island Explorer for local installation (http://
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6.4. Methylation PCR Primer Design Tools
(i) MethPrimer: CpG island prediction, MSP, MSI
primer design. By using this software 5  and 3 
ends of primer pair should have sites where con-
version has occurred (C to T). This is to avoid
ampliﬁcation bias towards the unconverted sequence
(http://www.urogene.org/methprimer/).
(ii) BiSearch: BSP and MSP primer design (http://bi-
search.enzim.hu/).
(iii) PerlPrimer: PerlPrimer is a free, open-source appli-
cation written in Perl that designs primers for
standard PCR, bisulﬁte PCR, real-time PCR (QPCR)
and sequencing. It aims to automate and simplify
the process of primer designing (http://perlprimer
.sourceforge.net/).
(iv) BiQ Analyzer: software tool for easy visualiza-
tion and quality control of DNA methylation
data from bisulﬁte sequencing (http://biq-analyzer.
bioinf.mpi-inf.mpg.de/).
6.5.MethylationBLAST(metthBLAST). methBLAST(http://
medgen.ugent.be/methBLAST/) is a sequence similarity
search program designed to explore in silico bisulﬁte modi-
ﬁed DNA (either or not methylated at its CpG dinucleotides)
to provide a search portal for validated methylation assays.
The tool is mainly developed to ﬁnd primer binding sites
and hence addresses speciﬁcity for PCR-based assays that use
bisulﬁteconvertedDNAasinputmaterial,including bisulﬁte
sequencing, methylation-speciﬁc PCR, COBRA, bisulﬁte-
PCR-SCCP (BiPS), Ms-SNuPE, and PCR melting curve
analysis.
7. Discussion
The large number of investigations such as human ep-
igenome project (HEP) and cancer studies focused on
DNA methylation analysis based on bisulﬁte modiﬁcation
provided valuable information about methylation vari-
able positions that might inﬂuence genes activity (http://
www.epigenome.org)[ 7, 16, 49, 50]. Increasing knowledge
about methylation status of genes involved in carcinogenesis
can lead to discovering new biomarkers that could be used
for early detection, management, diagnosis or therapeutic
approaches in cancer patients. Developing biomarkers by
methylation analyzing methods requires accuracy, sensi-
tivity, low-false-positive and false-negative rates and high-
throughput evaluation of single CpG sites. Although dif-
ferent useful technologies exist for methylation assessment,
no method is universal. While besides choosing a method
accordingtotypeofsamplesandpossessedlaboratoryspecial
equipment, right choice of CpG island and primer or probe
will minimize the risk of failed experiment.
Right primer and probe design is crucial for successful
PCR ampliﬁcation of bisulﬁte-modiﬁed DNA. Bisulﬁte reac-
tion not only causes the expected conversion of cytosines
to uracils, but also causes undesired DNA strand breakage.
Loss of DNA during the subsequent puriﬁcation step is
another concern especially when studying microdissected
DNA samples. All these factors pose challenges to down-
stream PCR applications and primacy of designing primers
and probe for such PCR-based assays. Mostly, ampliﬁcation
ofaproductsizegreaterthan500bpisdiﬃcultafterbisulﬁte-
modiﬁed DNA template; hence, it might be better to set the
default product size range as 100–500bp for primer design.
Another option that diﬀers from standard PCR is primer
length. Bisulﬁte conversion-based PCRs generally require
longer primers. Primers with a length of approximately
30merusuallyyieldsuccessfulresults[39].Thereasonisthat
bisulﬁte modiﬁcation decreases considerably GC content
of DNA templates and produces long stretches of “T”s in
the sequence that makes it diﬃcult to pick primers with
acceptable Tm values or stability. In other words, in order to
discriminatemodiﬁedDNAandunmodiﬁedorincompletely
modiﬁed DNA, enough number of “C”s is required in
primers and probes, which makes picking stable primers
more demanding. Thus, to achieve better duplex stability,
choosing longer primer is necessary as Tm of DNA. In
practice, size of primers for such PCR-based assays usually
ranges from 20 to 30mer [3, 40, 51].
Much more eﬀort is needed to validate an experiment for
clinical use of biomarkers such as easy to use method, sensi-
tivity and speciﬁcity, appropriate primers and probes, easily
interpretable results, and cost-eﬀectiveness. The guidelines
and the online web tools that are introduced in this review
might help to have a successful experiment and to develop
speciﬁc diagnosis biomarkers by designing right primer pair
and probe prior to experimental step.
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